|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Suppl. Tab. 2. Comparison of epidemiological MG studies using pyridostigmine registries** | | | | | | | | | |
| **Country** | **No of patients / country or study population** | **Methods** | **Years** | **Incidence per 100,000/ year** | **Prevalence per 100,000 inhabitants** | **Age related data** | **Sex related data** | **Changes over time** | **Comments** |
| **Poland** | 8,702 / 38,430,000 | at least one medical service coded in ICD-10 as myasthenia gravis (G70) and at least two prescriptions for pyridostigmine or ambenonium in two consecutive years | 2012-2018 | (2018) 2.36 | 22.65 | (2018) incidence EOMG 0.80, F:M 3.1:1, LOMG 4.98, F:M 1:1.01; mean age of incident cases: 61.4yrs, 64.1 for M, 59.2 for F | (2018) incidence 2.16 for M, 2.54 for F, prevalence 17.69 for M, 27.30 for F | increasing incidence and prevalence over 2013-2018 | pyridostigmine registries, nationwide |
| **Norway** | 435 / 4,737,171 | at least one of: 1) more than one pyridostigmine prescription 2) a receipt for pyridostigmine prescribed by neurologist 3) a receipt for myasthenia gravis code in Norwegian Prescription Database | 2004-2007 | (2007) 1.6 | 13.1 | (2007) incidence EOMG 0.70, LOMG 3.4; prevalence F:M 3:1 <50yrs, 1,5:1>=50yrs; mean age of incident cases: 59yrs, 64 for M 55 for F | (2007) incidence 1.4 for M, 1.8 for F; prevalence 9.2 for M, 17 F | NA | pyridostigmine registries, nationwide |
| **Australia** | 2,574 / 21,874,920 | at least one pyridostigmine prescription + exclusion of patients taking fludrocortisone, midodrine or eritropoetin; for incidence: eliminaion of patients in preceding 3yrs | 2009 | (2009) 2.5 | 11.7 | (2009) incidence 2.5; mean age of incident cases: 59yrs; 62 for M, 57 for F | (2009) incidence 2.2 for M, 2.8 for F | NA | pyridostigmine registries, nationwide |
| **Chile** | 447 (42 prescriptions + 405 surveys) / 622,391 (population of hospital territory) | hospital pharmacy registry of patients taking pyridostigmine in two consecutive years and data from nationwide survey | 2012-2013 | NA | 8.36 | mean age of incident case: 38.7 (survey data) | F:M 3.3.:1 | NA | pyridostigmine registries, hospital territory |
| **Denmark** | 112 / 484,862 (residents of Danish county) | every hospital contact coded as G70 and at least one pyridostigmine prescription + AChRAb registry | 1993-2008 | NA | NA | 66 (median of age) | F:M 4:1 <=40yrs; 0,8:1>=40yrs | NA | pyridostigmine registries, territory of the county |
| **Denmark** | 693 / 5,511,000 | hospital diagnosis of G70 and pyridostigmine prescription | 1996-2009 | (2009) 0.9 | NA | (2009) incidence 0.4 EOMG, 1.9 LOMG | F:M 1:0.24 20-29yrs, 1:2 70-79yrs | LOMG not on an increase | pyridostigmine registries, nationwide |
| **Colombia** | 258 / 3,527,000 | diagnosis of G70 + pyridostigmine prescription in the period of study | 1st Feb- 30th Apr 2015 | NA | 8.7 | NA | no differences in incidence between sexes | NA | pyridostigmine registries, 7.2% of population present in Audifarma S.A. registers |
| **Portugal** | 407 / 3,644,195 (population of the North region of Portugal) | hospital databases + pyridostigmine prescriptions registers | 2013 | 0.6 | 11.2 | mean age of incident case: 43.7yrs, incidence EOMG 0.4, LOMG 1.0; prevalence EOMG F: 14.4, M: 6.7; LOMG F: 8.5, M: 14.8 | incidence F:M EOMG 2.7:1, LOMG 0.95:1 | NA | pyridostigmine registries, territory of the region |

*NA- not applicable, EOMG- early onset Myasthenia Gravis; LOMG- late onset Myasthenia Gravis*